These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16910543)

  • 41. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients.
    Reynolds GP; Arranz B; Templeman LA; Fertuzinhos S; San L
    Am J Psychiatry; 2006 Oct; 163(10):1826-9. PubMed ID: 17012696
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Schneiderian first-rank symptoms associated with fluvoxamine treatment: a case report.
    Ueda N; Terao T; Ohmori O; Nakamura J
    Hum Psychopharmacol; 2003 Aug; 18(6):477-8. PubMed ID: 12923827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.
    Lane HY; Lee CC; Liu YC; Chang WH
    Pharmacogenomics; 2005 Mar; 6(2):139-49. PubMed ID: 15882132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
    Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
    J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacogenetics of psychotropic drug response.
    Malhotra AK; Murphy GM; Kennedy JL
    Am J Psychiatry; 2004 May; 161(5):780-96. PubMed ID: 15121641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.
    Zhang JP; Malhotra AK
    Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):9-37. PubMed ID: 21162693
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of anti-colitic effect of fluvoxamine against acetic acid-induced colitis in normal and reserpinized depressed rats.
    Minaiyan M; Hajhashemi V; Rabbani M; Fattahian E; Mahzouni P
    Eur J Pharmacol; 2015 Jan; 746():293-300. PubMed ID: 25460023
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Serious drug interaction between clozapine-Leponex and fluvoxamine-Fevarin].
    Olesen OV; Starup G; Linnet K
    Ugeskr Laeger; 1996 Nov; 158(48):6931-2. PubMed ID: 8984760
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
    Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
    J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics.
    Hamdani N; Bonnière M; Adès J; Hamon M; Boni C; Gorwood P
    Neurosci Lett; 2005 Mar; 377(1):69-74. PubMed ID: 15722190
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Very low dose quetiapine-induced galactorrhea in combination with venlafaxine.
    Pae CU; Kim JJ; Lee CU; Chae JH; Lee SJ; Lee C; Paik IH
    Hum Psychopharmacol; 2004 Aug; 19(6):433-4. PubMed ID: 15303249
    [No Abstract]   [Full Text] [Related]  

  • 53. Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics.
    Nnadi CU; Malhotra AK
    Curr Psychiatry Rep; 2007 Aug; 9(4):313-8. PubMed ID: 17880863
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
    Llerena A; Dorado P; Peñas-Lledó EM
    Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings.
    Serretti A; Artioli P; Lorenzi C; Pirovano A; Tubazio V; Zanardi R
    Int J Neuropsychopharmacol; 2004 Dec; 7(4):453-60. PubMed ID: 15458611
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
    Carrillo JA; Ramos SI; Herraiz AG; Llerena A; Agundez JA; Berecz R; Duran M; Benítez J
    J Clin Psychopharmacol; 1999 Dec; 19(6):494-9. PubMed ID: 10587283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EPMS under antidepressive therapy with fluvoxamine and concomitant antibiotic therapy with clindamycin.
    Jakob F; Wolf J
    Pharmacopsychiatry; 2007 May; 40(3):129. PubMed ID: 17541891
    [No Abstract]   [Full Text] [Related]  

  • 58. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.
    Fleeman N; Dundar Y; Dickson R; Jorgensen A; Pushpakom S; McLeod C; Pirmohamed M; Walley T
    Pharmacogenomics J; 2011 Feb; 11(1):1-14. PubMed ID: 20877299
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bupropion for depression in schizophrenia.
    Englisch S; Inta D; Eer A; Zink M
    Clin Neuropharmacol; 2010; 33(5):257-9. PubMed ID: 20852411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case of fluvoxamine intoxication demonstrating nonlinear elimination pharmacokinetics.
    Spigset O; Ohman R
    J Clin Psychopharmacol; 1996 Jun; 16(3):254-5. PubMed ID: 8784660
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.